Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease
29 juin 2022 16h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., June 29, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress
17 mai 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal...
Travere Therapeutics Reports First Quarter 2022 Financial Results
05 mai 2022 16h01 HE
|
Travere Therapeutics, Inc.
Submitted New Drug Application (NDA) for sparsentan in IgA nephropathy in March 2022 Results from Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria (HCU) presented at the Society...
Angion Provides Corporate Update and Reports Full Year 2021 Financial Results
30 mars 2022 16h05 HE
|
Angion Biomedica Corp.
-- Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases -- Ended the year with nearly $89M in cash and cash equivalents ...
Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
24 févr. 2022 16h01 HE
|
Travere Therapeutics, Inc.
NDA submission of sparsentan in IgA nephropathy on-track for first quarter 2022 Company positioned for potential NDA submission for accelerated approval of sparsentan in FSGS and combined IgA...
Travere Therapeutics Provides Corporate Update and 2022 Outlook
10 janv. 2022 07h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for...
Angion Presents Multiple Posters on ANG-3070 at Kidney Week 2021, Including Preclinical Data and Design of Upcoming Phase 2 Study
05 nov. 2021 00h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Progress
28 oct. 2021 16h01 HE
|
Travere Therapeutics, Inc.
Recently reported positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan in IgA nephropathy Following pre-NDA interactions with FDA, NDA submission of...
Angion to Present Multiple Posters at Kidney Week 2021
18 oct. 2021 16h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand
15 sept. 2021 16h05 HE
|
Travere Therapeutics, Inc.
Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand Travere receives a $55 million upfront payment and is eligible for additional regulatory...